Analysis on lamivudine resistance mutations of patients with AIDS/CHB co-infection
10.3760/cma.j.issn.1003-9279.2016.05.014
- VernacularTitle:艾滋病合并慢性乙型肝炎感染患者对拉米夫定耐药的研究
- Author:
Simin HUANG
1
;
Weiping CAI
;
Fengyu HU
;
Baolin LIAO
;
Yun LAN
;
Youpeng CHEN
;
Xiaoping TANG
Author Information
1. 510630,暨南大学附属第一医院
- Keywords:
AIDS;
Hepatitis B,Chronic;
Co-infection;
Lamivudine;
Resistance mutations
- From:
Chinese Journal of Experimental and Clinical Virology
2016;30(5):473-476
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the prevalence and patterns of lamivudine (3TC) resistance mutations in acquired immune deficiency syndrome (AIDS)/chronic hepatitis B (CHB) co-infected patients receiving 3TC as a part of antiretroviral therapy.Methods Data of patients with AIDS/CHB co-infection from 2005 to 2010 were collected.HBV DNA was tested at the time of highly active antiretroviral therapy (HAART) and after 12,24,36,48 and 60 months therapy.HBV reverse transcriptase (RT) was amplified in detectable samples.3TC resistance mutations were identified.Results 185 co-infected patients were enrolled.3TC resistance mutations were negative at the time of HAART.3TC resistance mutations occurred in 29 co-infected patients after treatment,of these,7 patients were detected resistance mutations in two different points.9 patients were HBV non-viraemia at the time of antiviral therapy.Resistance mutations were detected after 12 months therapy in 3 patients.Patients with 3TC resistance mutations were more frequently HBeAg positive (65.5％ vs.33.3％,P =0.001),had higher HBV viral load (7.49 copies/ml vs.6.59 copies/ml,P =0.017) and longer duration of 3TC (40 months vs.26.5 months,P ＜ 0.001) than patients without 3TC resistance mutations.Four patterns of 3TC resistance mutations were detected:rtM204I (n=7),rtL180M (n=2),rtL180M + rtM204V/I (n =23) and rtL80V +rtM204I (n=4).Conclusions The prevalence of 3TC resistance mutations is low among AIDS/CHB co-infected patients in Guangzhou.Patients with HBV DNA negative before HAART are likely to develop resistance early during therapy.
